title: Effects of short- and long-term growth hormone replacement on lipoprotein composition and on very-low-density lipoprotein and low-density lipoprotein apolipoprotein B100 kinetics in growth hormone-deficient hypopituitary subjects.
abstract: In this study, we concurrently examined the effects of 8 and 40 weeks of growth hormone replacement (GHR) on lipids, lipoprotein composition, low-density lipoprotein (LDL) size, very-low-density lipoprotein (VLDL) apolipoprotein (apo)B kinetics and LDL apoB kinetics. Eight weeks of GHR did not alter lipid profiles. Forty weeks of GHR increased high-density lipoprotein-cholesterol (HDL-C) concentration (P =.01), nonsignificantly reduced LDL-C (P =.06), and reduced the HDL/LDL-C ratio (P =.04). Forty weeks of GHR increased HDL free cholesterol (P =.03), total cholesterol (P =.01), and cholesterol ester (P <.01) concentrations. No other significant changes in VLDL, LDL, or HDL composition or LDL size were noted at any time. Eight weeks of GHR reduced VLDL apoB absolute secretion rate (ASR, P =.03), with nonsignificant reductions in fractional secretion rate (FSR, P =.09) and pool size (P =.09). After 40 weeks of GHR, the VLDL apoB ASR, FSR, and pool size were not significantly different from baseline. Forty weeks of GHR increased both LDL apoB FSR (P =.02) and LDL apoB ASR (P =.04), with a small decrease in pool size. Thus, GHR may have important antiatherogenic effects; HDL-C increased, LDL-C was nonsignificantly reduced, the total/HDL-C ratio was reduced, VLDL apoB production was reduced, and LDL apoB turnover was increased.
authors.affiliation: Department of Metabolic Medicine, St. Mary's Hospital Campus, London, UK.
authors.forename: Tara
authors.initials: T
authors.lastname: Kearney
authors.forename: Carmen Navas
authors.initials: CN
authors.lastname: de Gallegos
authors.forename: Anthony
authors.initials: A
authors.lastname: Proudler
authors.forename: Kim
authors.initials: K
authors.lastname: Parker
authors.forename: Victor
authors.initials: V
authors.lastname: Anayaoku
authors.forename: Peter
authors.initials: P
authors.lastname: Bannister
authors.forename: Soundararajan
authors.initials: S
authors.lastname: Venkatesan
authors.forename: Desmond G
authors.initials: DG
authors.lastname: Johnston
mesh_terms: D000328:Adult; D000368:Aged; D000465:Algorithms; D001055:Apolipoproteins B / Q000378:metabolism*; D015992:Body Mass Index; D004311:Double-Blind Method; D005260:Female; D013006:Growth Hormone / Q000627:therapeutic use*; D019382:Human Growth Hormone / Q000172:deficiency*; D006801:Humans; D007018:Hypopituitarism / Q000097:blood* / Q000188:drug therapy*; D007651:Keto Acids / Q000097:blood; D007700:Kinetics; D008074:Lipoproteins / Q000097:blood*; D008077:Lipoproteins, LDL / Q000097:blood*; D008079:Lipoproteins, VLDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010316:Particle Size; D011986:Receptors, Somatotropin / Q000187:drug effects / Q000378:metabolism
chemical_list: D001055:Apolipoproteins B; D007651:Keto Acids; D008074:Lipoproteins; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D011986:Receptors, Somatotropin; D019382:Human Growth Hormone; C015963:2-ketopentanoic acid; D013006:Growth Hormone